A few other drug pricing items to keep an eye on this week:
E&C moves on CREATES: The Energy and Commerce Committee will hold a markup Wednesday on the slate of drug pricing bills it cleared out of the health subcommittee last week, including the infamous generic competition bill, the CREATES Act. Republicans on the subcommittee raised some serious concerns with the bill at that markup, but Democrats seem intent on pushing it forward.
That's true over on the House Judiciary Committee, too, where Democrats don't seem to want to change the bill, and may even decide it doesn’t need its own markup. “We’re ready to move it,” Rep. David Cicilline (D-R.I.), the chair of the panel’s antitrust subcommittee and the lead sponsor on CREATES, told me after the E&C hearing. “This has been a collaborative process. It’s been bipartisan from the beginning. I think it’s pretty baked.”
DeGette digs into insulin: Rep. Diana DeGette's Energy and Commerce subcommittee will hold its first of two hearings on insulin affordability today. The real drama, however, will come next week when the Colorado Democrat's committee is expected to hear from insulin makers as well as the pharmacy benefit managers often blamed for causing insulin makers to spike their prices year after year.
That's true over on the House Judiciary Committee, too, where Democrats don't seem to want to change the bill, and may even decide it doesn’t need its own markup. “We’re ready to move it,” Rep. David Cicilline (D-R.I.), the chair of the panel’s antitrust subcommittee and the lead sponsor on CREATES, told me after the E&C hearing. “This has been a collaborative process. It’s been bipartisan from the beginning. I think it’s pretty baked.”
DeGette digs into insulin: Rep. Diana DeGette's Energy and Commerce subcommittee will hold its first of two hearings on insulin affordability today. The real drama, however, will come next week when the Colorado Democrat's committee is expected to hear from insulin makers as well as the pharmacy benefit managers often blamed for causing insulin makers to spike their prices year after year.
No hay comentarios:
Publicar un comentario